Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Fox

Showing results (11-20 of 158) with videos related to

Pageof 16
Sort By:
Evidence-Based Cardiovascular Medicine|December 29, 2005
Abciximab with low-dose heparin prevented complications following percutaneous coronary revascularization without increased bleeding riskK A Fox
Evidence-Based Cardiovascular Medicine|December 29, 2005
Abciximab reduced short-term rates of death, MI and repeat revascularization in patients with refractory unstable angina undergoing PTCAK A Fox
Psychopharmacology Bulletin|April 1, 1975
Benzodiazepines, reproduction, and developmentK A Fox
Heart (British Cardiac Society)|September 2, 1999
Low molecular weight heparin (enoxaparin) in the management of unstable angina: the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary EventsK A Fox
Cardiovascular Drugs and Therapy|August 10, 1999
Have we reached the limit with thrombolytic therapy?K A Fox
European Heart Journal|July 4, 1998
Low molecular weight heparins in acute coronary syndromesK A Fox
The American Journal of Cardiology|December 5, 1991
Comparative analysis of long-term mortality after thrombolytic therapyK A Fox
Evidence-Based Cardiovascular Medicine|December 29, 2005
Eptifibatide did not significantly reduce the rate of adverse events in patients undergoing percutaneous coronary revascularizationK A Fox
Clinical Cardiology|March 1, 1990
The safety of anistreplase from the placebo-controlled AIMS study (anistreplase Intervention Mortality Study). The AIMS Study GroupK A Fox
European Heart Journal|July 1, 1995
r-hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot studyK A Fox
Pageof 16

Showing results (11-20 of 158) with videos related to

Sort By:
Pageof 16
Evidence-Based Cardiovascular Medicine|December 29, 2005
Abciximab with low-dose heparin prevented complications following percutaneous coronary revascularization without increased bleeding riskK A Fox
Evidence-Based Cardiovascular Medicine|December 29, 2005
Abciximab reduced short-term rates of death, MI and repeat revascularization in patients with refractory unstable angina undergoing PTCAK A Fox
Psychopharmacology Bulletin|April 1, 1975
Benzodiazepines, reproduction, and developmentK A Fox
Heart (British Cardiac Society)|September 2, 1999
Low molecular weight heparin (enoxaparin) in the management of unstable angina: the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary EventsK A Fox
Cardiovascular Drugs and Therapy|August 10, 1999
Have we reached the limit with thrombolytic therapy?K A Fox
European Heart Journal|July 4, 1998
Low molecular weight heparins in acute coronary syndromesK A Fox
The American Journal of Cardiology|December 5, 1991
Comparative analysis of long-term mortality after thrombolytic therapyK A Fox
Evidence-Based Cardiovascular Medicine|December 29, 2005
Eptifibatide did not significantly reduce the rate of adverse events in patients undergoing percutaneous coronary revascularizationK A Fox
Clinical Cardiology|March 1, 1990
The safety of anistreplase from the placebo-controlled AIMS study (anistreplase Intervention Mortality Study). The AIMS Study GroupK A Fox
European Heart Journal|July 1, 1995
r-hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot studyK A Fox
Pageof 16